Pathstone Holdings LLC Acquires 3,070 Shares of Insmed Incorporated (NASDAQ:INSM)

Pathstone Holdings LLC grew its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 9.5% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 35,544 shares of the biopharmaceutical company’s stock after purchasing an additional 3,070 shares during the period. Pathstone Holdings LLC’s holdings in Insmed were worth $2,595,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of INSM. V Square Quantitative Management LLC purchased a new stake in Insmed in the 3rd quarter valued at $30,000. EntryPoint Capital LLC purchased a new stake in shares of Insmed in the first quarter valued at about $33,000. GAMMA Investing LLC lifted its position in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 287 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares in the last quarter.

Insider Buying and Selling

In other news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. This represents a 27.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at $7,951,559.28. This represents a 11.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,882 shares of company stock worth $5,765,446. Corporate insiders own 4.60% of the company’s stock.

Insmed Stock Performance

Shares of INSM opened at $74.09 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market capitalization of $13.25 billion, a price-to-earnings ratio of -13.35 and a beta of 1.12. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The stock’s 50-day simple moving average is $72.04 and its 200 day simple moving average is $66.60.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same period in the prior year, the company posted ($1.10) earnings per share. The company’s quarterly revenue was up 18.1% compared to the same quarter last year. Research analysts forecast that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on INSM. StockNews.com downgraded Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. Bank of America upped their price objective on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Stifel Nicolaus lifted their target price on Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $83.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.